ALK Fusion

CI-VAR-00001181Explore in graph →CIViC 514

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Inflammatory Myofibroblastic Tumor2
ALK F1174L AND RANBP2::ALK Fusion	Crizotinib	Predictive	C	Supports Resistance	3	accepted	EID32 In a patient with RANBP2::ALK-positive inflammatory myofibroblastic tumor, acquisition of the ALK F1174L mutation following crizotinib treatment was associated with acquired resistance. Ba/F3 studies … (full text at CIViC) PMID 21030459 · Sasaki et al., 2010 · Open in CIViC	civic
RANBP2::ALK Fusion	Crizotinib	Predictive	C	Supports Sensitivity Response	4	accepted	EID1244 ALK-rearrangements are seen in 50% of inflammatory myofibroblastic tumor (IMT) cases. A 44 year old man was diagnosed with IMT. He was treated with surgery and catheter placement for administration o… (full text at CIViC) PMID 20979472 · Butrynski et al., 2010 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.